Omeprazol Stada (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Stada, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Omeprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Stada is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder. - Erosive esophagitis: aids the healing of erosive damage to the oesophagus. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development when patients require long‑term NSAID therapy.

Omeprazol Stada may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Diarrhea: loose stools occurring during treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: inflammation of kidney interstitium. - Hypomagnesemia: low magnesium levels with prolonged use. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fracture risk: potential decrease in bone mineral density with long‑term therapy.

When using OmOmni  

-     -  … ... ...   -  ...

The